Media headlines about NanoString Technologies (NASDAQ:NSTG) have been trending somewhat positive on Monday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NanoString Technologies earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.059776492622 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

A number of analysts have recently commented on NSTG shares. Zacks Investment Research lowered NanoString Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. BidaskClub lowered NanoString Technologies from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th. Cowen and Company reissued a “buy” rating and set a $20.00 price target on shares of NanoString Technologies in a research note on Thursday, September 28th. Janney Montgomery Scott lowered NanoString Technologies from a “buy” rating to a “neutral” rating in a research note on Thursday, October 12th. Finally, Robert W. Baird reissued a “buy” rating and set a $14.00 price target on shares of NanoString Technologies in a research note on Tuesday, October 24th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $17.25.

Shares of NanoString Technologies (NASDAQ NSTG) traded up $0.53 during mid-day trading on Monday, hitting $8.32. The stock had a trading volume of 297,819 shares, compared to its average volume of 408,915. NanoString Technologies has a 12-month low of $7.32 and a 12-month high of $23.45. The company has a current ratio of 4.22, a quick ratio of 3.74 and a debt-to-equity ratio of 0.93.

NanoString Technologies (NASDAQ:NSTG) last released its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.11. NanoString Technologies had a negative return on equity of 227.21% and a negative net margin of 44.24%. The business had revenue of $27.02 million during the quarter, compared to analysts’ expectations of $26.27 million. During the same quarter last year, the business posted ($0.51) EPS. The business’s revenue was up 12.9% on a year-over-year basis. equities analysts predict that NanoString Technologies will post -2.26 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect NanoString Technologies (NSTG) Share Price” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at

NanoString Technologies Company Profile

NanoString Technologies, Inc develops, manufactures and sells intuitive products that unlock scientifically valuable and clinically actionable biologic information from minute amounts of tissue. The Company is engaged in the development, manufacture and commercialization of instruments, consumables and services for profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample.

Insider Buying and Selling by Quarter for NanoString Technologies (NASDAQ:NSTG)

Receive News & Ratings for NanoString Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.